Biolexis Therapeutics, Inc.
Biolexis Therapeutics is a pharmaceutical company with an innovative, chemical-biological approach to accelerate drug discovery. Our AI enabled process, Moleculern, leverages our proprietary library of fragments, NCEs and wet-lab data to identify and design novel molecules targeting any class of protein with unprecedented speed and accuracy. Our process produces active, safe, and effective NCEs while reducing costs and increasing the probability of success in the clinic. Seven MolecuLern-generated agents have been licensed and are currently in phase I/II clinical trials. Let us work with you.